Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
BridgeBio (Nasdaq: BBIO) reported Q3 2025 revenue of $120.7M, driven by $108.1M in U.S. Attruby net product sales. As of Oct 25, 2025, 5,259 prescriptions from 1,355 prescribers were written since FDA approval in Nov 2024. The company ended the quarter with $645.9M in cash, cash equivalents and marketable securities.
Clinical highlights include positive topline FORTIFY results for BBP-418 (glycosylated αDG increased 1.8x at 3 months; serum CK reduced 82%; ambulation and FVC improvements) and positive CALIBRATE results for encaleret (76% of participants achieved serum and urine calcium targets at Week 24 vs 4% on conventional therapy). BridgeBio plans NDAs for BBP-418 and encaleret in 1H 2026.
BridgeBio (Nasdaq: BBIO) reported positive topline Phase 3 results from CALIBRATE for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) on October 29, 2025. The trial met its primary and key secondary endpoints with 76% of encaleret-treated participants reaching target serum and urine calcium at Week 24 versus 4% on conventional therapy (p<0.0001), and 91% achieving intact PTH above the lower reference limit versus 7% on conventional therapy (p<0.0001).
Additional readouts: mean corrected calcium increase of 0.82 mg/dL, mean 24-hour urine calcium reduction of 200 mg/day, 98% in target serum calcium at Week 20, and no discontinuations due to study drug. An NDA submission is planned in H1 2026; pediatric and chronic hypoparathyroidism registrational studies are planned in 2026.
BridgeBio (Nasdaq: BBIO) will release topline results from the ADH1 CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Management will discuss the data on a conference call at 8:00 a.m. ET the same day.
Investors can access a live webcast via the company’s Investors > Events and Presentations page and a replay will be available on the BridgeBio website for 90 days after the event.
BridgeBio (Nasdaq: BBIO) reported positive topline Phase 3 FORTIFY results for oral small molecule BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on Oct 27, 2025. Key clinical and biomarker readouts at the planned 12-month interim analysis met endpoints with a favorable safety profile.
Highlights include a 1.8x increase in glycosylated αDG (~17% of control, p<0.0001) sustained to 12 months, an 82% reduction in serum CK (p<0.0001), ambulatory improvement of +0.14 m/s from baseline and +0.27 m/s vs placebo (p<0.0001), and pulmonary benefit of ~+3% predicted FVC from baseline and ~+5% vs placebo (p=0.0071). The company intends to file an NDA with the FDA in H1 2026.
BridgeBio (Nasdaq: BBIO) announced two investor events next week: a webinar to share topline Phase 3 interim results from the LGMD2I/R9 FORTIFY study on Monday, October 27, 2025 at 8:00 AM ET, and its Q3 2025 earnings call on Wednesday, October 29, 2025 at 4:30 PM ET. Management will host both business update calls and provide webcasts accessible via the company’s Investors > Events and Presentations page.
A replay of each webcast will be available on the BridgeBio investor website for 90 days following the events.
BridgeBio Pharma (Nasdaq: BBIO) announced that on October 2, 2025 its compensation committee approved inducement RSU grants to 11 new employees totaling 23,884 shares of common stock under the Amended and Restated 2019 Inducement Equity Plan.
Vesting: 25% of each award vests on November 16, 2026, then 1/12 of the remaining shares vest quarterly thereafter, contingent on continued employment. All awards were granted as inducements pursuant to Nasdaq Listing Rule 5635(c)(4). The Plan was originally adopted November 2019 and amended on Feb 10, 2023 and Dec 13, 2023.
BridgeBio Pharma (Nasdaq: BBIO) presented groundbreaking data from the ATTRibute-CM study showing that acoramidis, their oral TTR stabilizer, demonstrates rapid efficacy in treating ATTR-CM (transthyretin amyloid cardiomyopathy). The drug showed significant cardiovascular benefits within the first month of treatment.
Key findings include a 49% hazard reduction in cardiovascular mortality or recurrent hospitalizations through Month 30 (p<0.0001), with 53 events avoided per 100 treated participants. At Month 42, continuous acoramidis treatment reduced cardiovascular mortality by 45% compared to placebo-to-acoramidis switch (p=0.0011).
Acoramidis, marketed as Attruby® in the US and BEYONTTRA® in Europe, Japan, and the UK, has received regulatory approval with labels specifying near-complete TTR stabilization.
BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming participation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 in Minneapolis from September 26-29. The company will present new data about Acoramidis for ATTR-CM treatment through five scientific presentations, including a late-breaking clinical trials session.
The presentations will cover various aspects of Acoramidis treatment, including its effects on cardiovascular outcomes, mortality rates, NT-proBNP levels, and cardiac conduction abnormalities in patients with transthyretin amyloid cardiomyopathy. Distinguished researchers from leading institutions will present the findings across oral and poster sessions.
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced several inducement grants of restricted stock units (RSUs) to new employees. The compensation committee approved RSU grants totaling 238,168 shares across 74 new employees between June and September 2025.
The RSU grants follow a consistent vesting schedule, with 25% of shares vesting after one year and the remaining shares vesting quarterly over the following three years, contingent on continued employment. These grants were made under the Company's Amended and Restated 2019 Inducement Equity Plan.
BridgeBio Pharma (Nasdaq: BBIO) announced positive Phase 2 proof-of-concept results for encaleret in treating post-surgical hypoparathyroidism. The study showed that 80% of participants achieved normal blood and urine calcium levels within 5 days of treatment, compared to 0% on conventional therapy.
The oral therapy demonstrated PTH-independent normalization of calcium levels, with nine participants showing rapid and sustained reduction in fractional excretion of calcium. The drug was well-tolerated with no serious adverse events reported. Based on these promising results, BridgeBio plans to initiate a registrational clinical study in 2026.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
